The effects of SB 206284A, 1-[7-(4-benzyloxy phenoxy)heptyl] piperidine hydrochloride, have been investi gated in vitro on calcium and sodium currents in rat-cultured dorsal root ganglion (DRG) neurones and potassium-mediated calcium influx in rat synaptosomes, Cardiovascular hemody namic effects in both anesthetized and conscious rats, and neu roprotective attivity in in vivo cerebral ischemia models were also investigated. In the rat DRG cells, SB 206284A caused almost complete block of the sustained inward Ca2+ current (IC50 = 2.4f.LM), suggesting that the compound is an effective blocker of slowly inactivating, high-voltage calcium current SB 206284A reduced locomotor hyperactivity in the gerbil bi-
The use of calcium-channel antagonists in ischemic brain injury has been extensively studied in animal mod els (Sauter and Rudin, 1986; Van Reempts et aI" 1987; Alps et aI, 1988; Ito et aI, 1994) , but a consistently ef fective compound has yet to be discovered. For example, although the calcium-channel antagonist nimodipine has been reported to be neuroprotective in some studies (Gotoh et aI" 1986; Germano et aI" 1987) , it had no effect on lesion volumes in other experiments (Snape et aI" 1993; Womack et aI" 1993) , Similarly, isradipine (PN200-1 1O)-reduced ischemic injury in some (Abe et aI" 1988; Sauter et aI" 1989) , but not all (Marinov and lateral carotid artery occlusion model without affecting isch emia-induced damage in the hippocampal CAl region, In the rat middle cerebral artery occlusion model, SB 206284A re duced lesion volume in the posterior forebrain, and in the rat photochemical cortical lesion model, lesion volume was re duced even when treatment was delayed until 4 hours after occlusion, At neuroprotective doses, SB 206284A had no car diovascular effects, These findings show that SB 206284A is a novel calcium channel antagonist that shows neuroprotective properties, Key Words: Calcium-Stroke-Cortical infarc tion-Global ischemia, Wassman, 1991) , experiments. Both of these compounds are dihydropyridines, a class of calcium antagonists known for their preferential vasodilator properties, so it is possible that at least some of their apparent neuropro tective effects are caused by changes in blood pressure and cerebral blood flow rather than neuroprotection. This is especially true of isradipine, in which predosing in spontaneously hypertensive rats to the level at which their blood pressure was normalized, attenuated the neu roprotective efficacy of this drug (Sauter and Rudin, 199 1) , This feature is caused by the action of dihy dropyridines at L-, and possibly T -, type channels, the only types found in smooth and cardiac muscle. How ever, neuronal tissue contains an additional number of neurone-specific channels (e,g., N and P), so an alterna tive approach to the development of L-channel selective compounds is to concentrate on those that show activity at all neuronal calcium channels. SB201823-A is such a compound because it is selective for calcium channels over sodium and potassium channels, but has little se lectivity for the different subtypes of calcium channels (Benham et aI., 1993) . We have previously shown the neuroprotective efficacy of this novel, nonpeptide, cal cium-channel antagonist in both the gerbil bilateral ca rotid artery occlusion (BCAO) and rat photothrombotic lesion models (Benham et aI., 1993) . In addition, SB20 1823-A reduced lesion volume in a rat middle ce rebral artery occlusion (MCAO) model but also caused a decrease in heart rate at a neuroprotective dose (Barone et aI., 1995) .
In the present studies, we describe the neuroprotective profile of a new calcium antagonist, SB 206284A [1-[7-(4-benzyloxyphenoxy)heptyl] piperidine hydrochloride], in models of cerebral ischemia and also show its lack of systemic cardiovascular properties in the rat. Some of this work has recently been presented in abstract form (Campbell et aI., 1995; Wood et aI., 1995) .
MATERIALS AND METHODS
All procedures used in this study were performed in accor dance with either the Animals (Scientific Procedures) Act (1986) 
Electrophysfological studies
Sensory neurones from dorsal root ganglia (DRG) were dis sociated from I-day-old rat pups using the method of Forda and Kelly (\985). Cells were plated out onto glass coverslips and used within 24 hours for sodium current measurements to per mit effective voltage clamp of the currents. Calcium currents (using barium as charge carrier) were measured in cells up to 4 days in culture. Whole-cell membrane currents were recorded using standard patch-clamp techniques.
The internal solution in the patch pipette contained 130 mM cesium chloride, 10 mM N-2-hydroxyethylpiperazine-N-2 eth anesulfonic acid (HEPES), 10 mM ethylene glycol-bis (13aminoethyl ether)-N,N-tetraacetic acid (EGTA), 4 mM magne sium chloride, and 2 mM ATP, buffered to pH 7.2 with cesium hydroxide. For sodium current measurements 5 mM sodium chloride was added to the internal solution. The external solu tion for measuring sodium currents contained 145 mM sodium chloride, 2.5 mM potassium chloride, 10 mM glucose, 10 mM HEPES, 1.2 mM magnesium chloride, 0. 15 mM calcium chlo ride, and 0. 1 mM cadmium chloride buffered to pH 7.4 with sodium hydroxide. The external solution for recording calcium channel currents consisted of 10 mM barium chloride, 130 mM tetraethyl ammonium (TEA) TEA-CI, 10 mM glucose, 10 mM HEPES, 1 mM magnesium chloride and 0.00 1 mM tetrodotox in, buffered to pH 7.3 with TEA-OH.
All experiments were performed at 21-24°C. Test com pounds were dissolved in dimethyl sulphoxide to make a 20 mM stock solution. At the maximum drug concentration used, the vehicle (0. 1 %) had no effect on calcium currents.
Calcium influx
Synaptosomes were prepared from the cerebral cortex of male Sprague-Dawley rats (200-300 g), using isotonic sucrose/ Percoll discontinuous density gradient centrifugation, by a method adapted from that of Dunkley et al. (1987) . The syn- Rats were allowed to recover from surgery for at least 7 days before experimentation.
On the day of observation, rats were placed individually in conical restrainers and the cannulae were flushed with hepa rinized saline (250 U/ml). The arterial cannula was connected to a arterial pressure transducer and the arterial blood pressure and heart rate (electronically derived from the arterial blood pressure signal) were continuously recorded using a multichan nel recorder. After a I-hour stabilization period, SB206284A
(10 mg/kg) or vehicle (as above) (1.5 ml) were infused intra venously [IV] during a 15-min period and mean arterial pres sure and heart rate were monitored for 4 hours.
Ischemia models
All animals were housed singly under standardized environ mental conditions (12 h light/dark cycle, 21 ± 1°C, and 55 ± 5% humidity) and allowed free access to food and water.
Gerbil bilateral carotid artery occlusion. Male Mongolian gerbils (B & K, UK), in the weight range 50-70 g, were anes thetized with halothane in oxygen. Core body temperature was maintained at 37 ± 1°C with a heating blanket. The common carotid arteries were clamped with atraumatic aneurysm clips for 10 min. Blood flow was then reestablished on removal of the clips. The wound was then sutured closed and the animal allowed to recover for 2 hours in an incubator with an ambient temperature of 33-35°C. After recovery, the gerbils were housed individually with access to food and water ad libitum.
Sham animals underwent the same surgical procedure but their carotid arteries were not isolated or clamped.
SB 206284A was administered IP at a dose of 30 mg/kg 30 min after occlusion, then at 10 mg/kg twice a day for 3 days.
The vehicle s"as 10% hydroxypropyl �-cyclodextrin in saline. At 24 and 48 hours after surgery, a neurologic examination was performed, as previously described (Barone et aI., 1995) .
Briefly, the animals were tested for hindlimb placement and degree of hemiparesis.
Forty-eight hours after MCAO, the rats were killed by so dium pentobarbitone overdose, and their brains removed. in the entire forebrain for each animal as previously described (Barone et aI., 1992; 14.5 mm, midline minus 2.5 mm. Rose Bengal, 20 mg/kg, was infused during a period of 60 s into the intravenous cannula.
The skull was then illuminated for 5 minutes, after which the light guide was moved to the other side of the skull (midline plus 2.5 mm), and the light switched on for an additional 5 minutes. The scalp wound was closed using subcuticular stitches and cyanoacrylate tissue adhesive was applied.
Throughout the procedure, rectal temperature was maintained at 37 ± I DC by a heated blanket with feedback control.
Drug administration was initiated 10 min after illumination;
SB 206284A (10 mg/kg) or vehicle (10% hydroxypropyl-/3cyclodextrin) was infused via the intravenous cannula during a period of 15 min. The intravenous cannula was then removed, after which the animals were placed in recovery cages under infrared heating lamps to recover fully before being returned to their home cages.
Histologic procedures in photothrombotic model. 
RESULTS

Electrophysiologic studies
In DRG cells, application of SB 206284A caused a concentration-dependent reduction in calcium current. B SB 206284 in blocking sustained current relative to peak current might be explained by voltage-dependent block of the current. When applied to cells pretreated with 10 mM nimodipine (to block L type currents), and to other cells pretreated with 10 ILM m-conotoxin GVIA (mCTX GVIA) (to block N-type currents), the inhibitory effects of SB 206284A show little difference in IC50 indicating little subtype selectivity of this compound (Table 1) . However SB 206284A was less potent as a blocker of voltage-gated sodium currents evoked in DRG neurons (Table 1 and Figure IB) . Intracellular administration of SB 206284A, by addi tion to the patch pipette internal solution, resulted in significantly weaker block of total DRG calcium current than when applied extracellularly. SB 206284A, 50 and 100 ILM, was applied intracellularly to two separate batches of cells. The degree of block was assessed by measuring the calcium current 3 min after breakthrough relative to the first calcium current measured within 30 s of breakthrough. These two doses blocked 17 ± 12% (n = 4) and 14 ± 16% (n = 4) of the calcium current respectively. Current block of this magnitude cannot be accurately dissociated from possible cell rundown. When applied extracellularly to the same two batches of cells, 20 ILM SB 206284A blocked 82 ± 24% (n = 4) and 83 ± 31 % (n = 4) of the current respectively. The results suggest that the binding site for SB 206284A is located on the extracellular surface of these neurones and that the binding site cannot be accessed by this compound from an intracellular location, e.g., by traversing the cell mem brane.
Calcium influx in synaptosomes SB 206284A was tested for its potency in inhibiting potassium-stimulated calcium elevation in cortical syn aptosomes, a model for presynaptic calcium entry. At concentrations up to 100 ILM, SB 206284A had no sig- 2.4 (n = 4) 3.5 (n = 4) 5.6 (n = 3-5) 16.5 (n = 2-4) nificant effect on basal calcium in cortical synaptosomes (Fig. 2) . However, SB 206284-A at concentrations of 50 and 100 fLM caused a 30% reduction in potassium stimulated calcium influx, with the lower concentration producing a significant decrease (p < 0.05). SB 206284A at concentrations of 100 fLM did not inhibit calcium in flux to any greater degree than did concentrations of 50 fLM, which suggests that SB 206284A blocks a subpop ulation of calcium channels that are present on cortical synaptosomes, but leaves unblocked a further subpopu lation that is responsible for the remainder of the potas sium-stimulated calcium influx. For comparison, SB20l823-A, which is effective in three models of isch emia, blocks all of the depolarization-induced calcium influx at concentrations greater than 50 fLM (Benham et al., 1993) . Selective blockers of L-and N-type calcium channels inhibit only a small component of this calcium influx. Thus� the maximal effect of the L-type channel antagonist nimodipine was a 7% block at a concentration of 10 fLM. 'U)'-CTX GVIA, at 1 fLM, a concentration that produces maximal block of N-type channels in rat DRG cells (Benham et aI., 1993) , blocked only a small pro portion of the potassium stimulated calcium release (Meakin and Smith, 1993 and unpublished data) .
Cardiovascular data
SB 206284-A (10 mg/kg IV over 30 min) did not significantly affect blood pressure or heart rate when compared with the respective vehicle group in both anes thetized and conscious rats (Tables 2 and 3) .
Ischemia studies
Gerbil bilateral carotid artery occlusion model. There was no difference in the extent of ischemic injury caused by 10 min BCAO in the hippocampal CAl region be tween drug-(administered IP after occlusion) and ve hicle-treated groups when determined 4 days after occlu sion (Fig. 3A) . However, SB 206284A caused a signifi cant reduction in the hyperactivity induced by 10 min global ischemia. (Fig. 3B) .
Rat middle cerebral artery occlusion model. Intrave nous infusion of SB 206284A, 10 mg/kg commencing 30 min after MCAO, significantly reduced both hemispheric swelling (Fig. 4A ) and infarct size in some areas of the posterior forebrain at 48 h (Fig. 4B) . SB 206284A did not cause an improvement in hindlimb neurologic defi cits (data not shown).
Rat photothrombotic lesion model. Under all dosing conditions SB 206284A significantly reduced lesion vol ume at 7 days in this model. The greatest effect (67% reduction in lesion volume) was produced when the com pound was administered as an intravenous infusion of 10 mg/kg over 15 minutes, beginning 10 min after surgery. The compound was also neuroprotective when given as several IP bolus doses, even when the first dose was delayed until 2 or 4 hours after surgery, resulting in a 54% reduction in lesion volume (Table 4) .
Marmoset photothrombotic lesion model. SB 206284A, when administered as a 10 mg/kg infusion over 15 min beginning 10 min after surgery, produced a nonsignificant reduction in lesion volume at 7 days (Table 4 ).
DISCUSSION
These results show that the structurally novel neuronal calcium-channel antagonist SB 206284A is neuroprotec tive in three models of cerebral ischemia at doses that show no systemic cardiovascular effects. This profile represents an improvement over that of existing calcium channel antagonists such as isradipine and SB20 1823-A which, although neuroprotective, significantly lower Values are mean ± SD. SB 206284-A (10 mg/kg was infused i.v. over 30 min). Values are mean ± SD. SB 206284-A (10 mg/kg was infused i.v. over 30 min).
blood pressure (Sauter and Rudin, 1991) and heart rate (Barone et aI., 1995) , respectively. SB 206284A shows little selectivity for L-or N-type channels when blocking high threshold calcium channels in rat DRG cells and has less selectivity for sodium than calcium channels in com parison with SB20 1823A. Voltage-dependent calcium uptake into synaptosomes is mediated primarily by chan nels insensitive to dihydropyridines and m CTX GVIA (Thomas et aI., 1994) . This could explain why SB 206284A, which we have shown acts on these channel subtypes, is effective in blocking only part of the calcium influx into rat cortical synaptosomes. A component of synaptosomal calcium influx (approximately 30%) is re ported to be lliocked by the P-channel ligand, m aga IV A (Thomas et aI., 1994) , but the present study did not ex amine whether SB 206284A does in fact block this chan nel subtype.
The effects of intravenously infused SB 206284A on blood pressure and heart rate in both anesthetized and conscious rats were insignificant. Thus, SB 206284A represents an important advance over SB20 1823-A, which produced a significant bradycardia (l00 beats/ min) when administered to conscious rats (Barone et aI., 1995) , because neuroprotective compounds devoid of SB 206284A was tested in three different models of cerebral ischemia in three species-one global (gerbil BCAO), and two focal (MCAO in rats, photothrombotic lesions in rats and marmosets) models. When adminis tered as several doses after occlusion in the gerbil, SB 206284A produced a marked reduction in ischemia induced hyperlocomotion, but no amelioration of hippo campal damage. This was an unexpected finding, espe cially because it has been suggested that hyperlocomo tion correlates with CA I neuronal loss (Gerhardt and Boast, 1988) . However, there is also evidence that it is possible to reduce CA I damage without decreasing lo comotor activity, implying that the two phenomena are not causally related (Gerhardt et aI., 1986) . Our data support this hypothesis by suggesting that the reverse is also true-it is possible to improve the functional deficit without preserving CAl neurones. In this study no dam age was detected in other brain areas, so the mechanism responsible for this ischemia-induced hyperiocomotion remains unclear. It has been suggested that damage to the entorhinal cortex, or to layers 2 and 3 of the somatosen sory cortex, may be involved (Kuroiwa et aI., 199 1) , but this was not observed in our study.
SB 206284A was effective in reducing the cortical injury generated in both the MCAO and photothrombotic models of focal cerebral ischemia in the rat. When ad ministered as a 10 mg/kg intravenous infusion in the MCAO model, SB 206284A decreased total hemispheric swelling and infarct volume in the posterior forebrain. In the case of the photothrombotic model, the same dose of SB 206284A, regardless of the route of administration (IP or IV), reduced lesion volume and was effective even when the first dose was delayed until 4 hours after sur gery. In the marmoset, the reduction in volume produced by 10 mg/kg IV SB 206284A did not reach statistical significance. Previously, we found that flunarizine at 10 mg/kg, administered intraperitoneally 30 min after isch emia and twite daily for 3 days, had no effect on lesion volume in this primate model (Milkowski et aI., 1994) . The failure of both SB 206284A and flunarizine to show neuroprotective efficacy may indicate that this primate variant of the photothrombotic lesion model is particu larly resistant to drug treatment. Although we have shown neuroprotection with SB201823-A (Benham et aI., 1993) , NBQX (Wood et aI., 1993) , and SB 206284A in the rat photothrombotic model, flunarizine (data not shown) was not effective. Similarly, isradipine failed to reduce lesion volume in either the gerbil BCAO or rat photothrombotic models (Bailey et aI.,1995) , although the drug had a positive effect in the rat MCAO model (White et aI., 1994) . These findings suggest that the BCAO and photothrombotic models are more resistant to amelioration by isradipine. Moreover, published data in the rat MCAO model are themselves equivocal (Sauter et aI., 1989; Marinov and Wassman, 1991) , showing that this dihydropyridine compound is not always effective even in the same model. Isradipine is not unique in this respect; the litera ture contains numerous examples of compounds that give positive results in some laboratories but not others. For example, the NMDA antagonist, MK-80l, has been reported to be neuroprotective in some ( Gill et aI., 1987) , but not other, experiments (Buchan & Pulsinelli, 1990; Li and Buchan, 1993) . The fact that these studies used different models adds to, rather than detracts from, the problem. In the absence of evidence showing that some models are clinically more relevant than others, it is desirable that new compounds should be neuroprotec tive in as many models as possible. Even if consensus is reached on which is the best model, there remain the questions of the ideal dosing regime and time of killing.
The choice of dosing protocol (pre-vs postocclusion) is an important consideration, especially as some com pounds have effects on vascular calcium channels. The 
Lesion volume (mm})
----�---------Vehicle 12.65 ± 4.53 (n = 9) 3.52 ± 2.75 (n = 10) 5.87 ± 3.93 (n = 9)
38.83 ± 7.98 (n = 6) Drug 6.71 ± 3.54 (n = 10) 1.63 ± 1.24 (n = 10) 1.93 ± 2.10 (n = 9) 31.41 ± 4.09 (n = 6) See Materials and Methods for full details of dosing schedules.
Significance p = 0.01 p = 0.03 p = 0.001 p = 0.07 dihydropyridines, in particular, reduce vascular resis tance in the brain (Harper et aI., 198 1; Haws et aI., 1983) , and it has been shown that pretreatment with nimodipine will increase cerebral blood flow in the penumbral region and reduce lesion volume (Mohamed et aI., 1985) . Therefore, dosing compounds preischemia are likely, partially, to prevent formation of the lesion, rather than salvage the neurones after insult. Because it is debatable whether this reflects a chronic neuroprotection, and as prophylactic treatment is unlikely to be an option in the clinic, preocclusion administration of drug candidates is not the best option for drug selection and, development. Therefore, SB 206284A possesses robust neuroprotec tive properties because it was found to be effective when administered after lesion induction, even when the first dose was delayed until 4 hours after surgery. Finally, the time allowed to elapse after occlusion be fore the animals are killed will greatly affect the assess ment of neuroprotection. The majority of published stud ies use short sacrifice times (48 hours or less), when lesion volume will be affected by the presence of edema. As calcium-channel antagonists such as the dihydropyri dines (nimodipine, nicardipine, isradipine) and diphenyl alky lamines (cinnarizine, flunarizine) also increase cere bral blood flow by dilating cerebral vessels, it is possible that the appar � nt reduction in lesion volume at short-time points, in part, may be caused by actions on vascular smooth muscle, increased cerebral blood flow, and sub sequent enhanced clearance of edema. The diversity of results may therefore reflect the multiple roles of calcium channels in vascular reactivity, neuronal activity, and capillary transport mechanisms. Abe et aI. (1988) sug gested that the neuroprotective effect of isradipine may be at least partially explained by a reduction in edema formation caused by inhibition of calcium accumulation. Our choice of killing times was selected on the basis that by 4 days after surgery in the gerbil, and 7 days after surgery in the rat and marmoset, edema is largely cleared, and delayed neuronal cell death almost com plete. Measurements of lesion volume are then not dis torted by the presence of large amounts of water. This distortion was corrected for in the rat MeAO model, in which killing at 48 hours is justified by measuring hemi spheric swelling as well as infarct size, the former mea surement giving an indication of the extent of edema in addition to neuronal damage.
The choice of models, dosing regimes and end points utilized in the current studies was an attempt to address the criticisms mentioned above. Neuroprotection was shown in both permanent focal models and one transient global ischemia model, after a after infarct SB 206284A dosing regimen. Edema was assessed postmortem (rat MeAO) and killing was delayed long enough to allow for clearance of edema (gerbil BeAO, rat and marmoset photothrombotic models). The absence of cardiovascular J Cereb Blood Flow Metab, Vol. 17. No, 4, 1997 side-effects, particularly in conscious rats, suggests that SB 206284A has a superior profile as a neuroprotectant.
In summary, our findings show that SB206284A is a novel neuroprotective agent with no cardiovascular ef fects at neuroprotective doses. Further work is needed to characterize fully the selectivity of this compound, and this should be possible using recombinant cell lines ex pressing specific SUbtypes of calcium channels.
